From 2016 to 2017, spending on both branded patent-protected drugs and branded specialty drugs rose even more rapidly at 5 percent and 10 percent, respectively.
Prescriptions greater than 30 days were broken out into 30-day increments.
2, prescription Drug Types, in general, prescription drugs can be allocated into two large typesgeneric drugs and branded drugs.
Branded Specialty Drug Trends, branded specialty drugs make up a small share of branded prescription drugs filled at 3 percent, but account for 34 percent of branded drug spending in 2017.The reduction can only be applied to brand drug spending in this report and only to the most recent iron man no cd year experience.Trend Update: Generic and Branded Drugs.Branded patent-protected prescription drugs make up 52 percent of branded prescription drugs filled, but account for 66 percent of total branded drug spending.This report defines branded specialty drugs as drugs sold under a brand name and used to treat complex, chronic health conditions, often requiring special handling, administration or monitoring.In addition to claims data from bcbs members, this study also leveraged external data sources.
The FDA defines exclusivity as refering to certain delays and prohibitions on approval of competitor drugs available under the statute that attach upon approval of a drug or of certain supplements.The impact will depend on the total dollars of drug rebates available, the annual growth rate of drug rebates and the ability of the drug rebate program to change market dynamics.Victoria Victoria, Mahe, Seychelles.From being made, used or sold by other manufacturers for a specific period of time.In the 2018 Health of America Trend Update, this categorization was refined by using FDA information to classify branded drugs based as either patent-protected or non-patent protected as of January 1, 2018.Using the Public Use Files from the Medical Loss Ratio reporting requirements as a proxy, bcbs has estimated a downward impact to the rate of drug spending experienced in the market in 2017 if rebates continued to grow in 2017 similar to rebate growth experienced.
Pharmacy claims were used to estimate total spending and utilization.